CeraShield™ resorbable envelope targets prevention of bacterial and highly lethal fungal infections and reduction of surgical site infections of pacemaker implantations
New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat
Plans to Initiate First-in-Human testing in First Quarter of 2018
CeraShield™ Coating Prevents Bacterial and Fungal Colonization, and Reduces Endotoxin
FDA Grants N8 Medical’s Request for Breakthrough Device Designation for its CeraShield™ Endotracheal Tube
A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and retains activity in various body fluids.
Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool available to treat multidrug resistant bacteria because bacteria were not exchanging genes for its resistance. Read more
On June 16, 2016 the Centers for Medicare & Medicaid Services (CMS) announced that it is proposing to update the requirements that hospitals and critical access hospitals (CAHs) must meet to participate in Medicare and Medicaid.
A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that CSA-131 is highly effective against Colistin resistant strains of Pseudomonas and Acinetobacter.